HomeCompareSZUKF vs EQR

SZUKF vs EQR: Dividend Comparison 2026

SZUKF yields 1.93% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $16.6K in total portfolio value
10 years
SZUKF
SZUKF
● Live price
1.93%
Share price
$30.30
Annual div
$0.59
5Y div CAGR
24%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$2,432.69
Full SZUKF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — SZUKF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZUKFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZUKF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZUKF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZUKF
Annual income on $10K today (after 15% tax)
$164.32/yr
After 10yr DRIP, annual income (after tax)
$2,067.79/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $2,586.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZUKF + EQR for your $10,000?

SZUKF: 50%EQR: 50%
100% EQR50/50100% SZUKF
Portfolio after 10yr
$39.5K
Annual income
$3,954.15/yr
Blended yield
10.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SZUKF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.7
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZUKF buys
0
EQR buys
0
No recent congressional trades found for SZUKF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZUKFEQR
Forward yield1.93%5.87%
Annual dividend / share$0.59$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24%15.8%
Portfolio after 10y$31.2K$47.8K
Annual income after 10y$2,432.69$5,475.61
Total dividends collected$9.6K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: SZUKF vs EQR ($10,000, DRIP)

YearSZUKF PortfolioSZUKF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,940$239.72$11,380$679.82$440.00EQR
2$12,009$303.91$13,014$837.25$1.0KEQR
3$13,237$386.64$14,961$1,036.20$1.7KEQR
4$14,657$493.86$17,297$1,289.22$2.6KEQR
5$16,317$633.73$20,121$1,613.15$3.8KEQR
6$18,277$817.58$23,561$2,030.84$5.3KEQR
7$20,617$1,061.28$27,783$2,573.54$7.2KEQR
8$23,448$1,387.40$33,013$3,284.39$9.6KEQR
9$26,918$1,828.58$39,547$4,223.51$12.6KEQR
10$31,235$2,432.69$47,791$5,475.61$16.6KEQR

SZUKF vs EQR: Complete Analysis 2026

SZUKFStock

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.

Full SZUKF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SZUKF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZUKF vs SCHDSZUKF vs JEPISZUKF vs OSZUKF vs KOSZUKF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.